CYBERDYNE (7779) AI Stock Analysis

• Market Cap: $39.58B
• Dividend Yield: N/A
• Average Volume (3M): 724.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.83
• Revenue Growth: -5.24%
• EPS Growth: 81.24%
• Country: JP
• Employees: 227
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 1.19
• Shares Outstanding: 137,445,820
• 10 Day Avg. Volume: 764,380
• 30 Day Avg. Volume: 724,970
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.83
• Enterprise Value/Revenue: 7.77
• Enterprise Value/Gross Profit: 14.54
• Enterprise Value/Ebitda: 122.60
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: ¥178.00 ▲(0.56% Upside)

CYBERDYNE's overall stock score is primarily impacted by its financial performance and valuation challenges. The company's declining revenues, negative profit margins, and poor cash flow generation are significant concerns. Additionally, the negative P/E ratio and lack of dividend yield further detract from its attractiveness. Technical analysis suggests bearish momentum, adding to the cautious outlook.

CYBERDYNE Business Overview & Revenue Model

Company Description

CYBERDYNE Inc. researches, develops, produces, sell, leases, and maintains equipment and systems for medical and warfare in Japan. The company offers Hybrid Assistive Limb (HAL) for medical use in lower limb and single joint type; non-medical HAL for lower limb, single joint type, and lumbar type; HAL peripherals; cleaning robots; transportation robots for various transportation tasks in factories, offices, and other indoor environments; and Acoustic X, a high speed light pulse LED array light source that enables real time photoacoustic imaging. It also provides Cybernics Treatment, a treatment that uses HAL to enhance/regenerate the function of the wearer for spinal cord injury, stroke, neuromuscular diseases, etc.; HAL FIT for enhancement of brain-nerve-musculoskeltal system; MTX Neuro HAL Plus to enhance the performance of the athletes' brain-nerve functions; and Neuro HALFIT for enhancement of physical functions. In addition, the company is involved in the provision of rescue supports in disaster sites, and heavy labor supports for factories and plants; and entertainment business. The company was incorporated in 2004 and is headquartered in Tsukuba, Japan.

How the Company Makes Money

CYBERDYNE generates revenue through multiple channels, including the sale of its robotic products such as the HAL exoskeleton, which is marketed to hospitals and rehabilitation centers. The company also earns income from leasing its robotic systems and providing maintenance and support services. Additionally, CYBERDYNE has formed strategic partnerships with healthcare providers and research institutions, which help to expand its market reach and promote the adoption of its technologies. Grants and funding for research projects further contribute to its revenue streams, particularly in the development of new applications and enhancements of existing products.

CYBERDYNE Financial Statement Overview

Summary

CYBERDYNE faces financial challenges with declining revenues and profitability issues, as reflected in negative margins and cash flows. The balance sheet remains a strength with low leverage, but the company needs to address operational inefficiencies and improve cash flow generation to enhance financial health.

Income Statement

CYBERDYNE's income statement shows a declining revenue trend with a negative revenue growth rate of -3.54% in the TTM. The company has a gross profit margin of 54.13%, which is relatively strong, but the net profit margin is negative at -13.14%, indicating losses. The EBIT and EBITDA margins are also negative, reflecting operational challenges.

Balance Sheet

The balance sheet is relatively stable with a low debt-to-equity ratio of 0.011, suggesting low leverage. However, the return on equity is negative at -1.43%, indicating inefficiencies in generating returns from equity. The equity ratio is strong, showing a solid capital structure.

Cash Flow

CYBERDYNE's cash flow statement reveals negative operating and free cash flows, with a significant decline in free cash flow growth at -59.64% in the TTM. The operating cash flow to net income ratio is negative, indicating cash flow challenges. However, the free cash flow to net income ratio is positive, suggesting some ability to cover net losses.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	4.23B	4.38B	4.35B	3.29B	2.15B	1.88B
Gross Profit	2.26B	2.37B	2.39B	1.79B	1.28B	1.30B
EBITDA	268.00M	16.00M	-2.00M	873.00M	116.00M	873.00M
Net Income	-337.00M	-577.00M	-1.48B	-298.00M	-498.00M	-59.00M
Balance Sheet
Total Assets	48.95B	48.55B	50.00B	50.19B	48.12B	47.81B
Cash, Cash Equivalents and Short-Term Investments	5.14B	14.86B	16.66B	17.31B	5.68B	6.70B
Total Debt	402.00M	434.00M	632.00M	669.00M	575.00M	421.00M
Total Liabilities	9.16B	8.95B	9.52B	8.20B	4.33B	3.55B
Stockholders Equity	39.76B	39.58B	40.75B	42.10B	43.41B	43.78B
Cash Flow
Free Cash Flow	-293.00M	-735.00M	-1.07B	-652.00M	-1.85B	-620.00M
Operating Cash Flow	-60.00M	-430.00M	-850.00M	-143.00M	-775.00M	-215.00M
Investing Cash Flow	460.00M	2.33B	-2.08B	2.17B	-2.79B	-244.00M
Financing Cash Flow	-216.00M	-216.00M	160.00M	14.00M	617.00M	1.30B

CYBERDYNE Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 177.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7779, the sentiment is Negative. The current price of 177 is below the 20-day moving average (MA) of 184.95, below the 50-day MA of 192.58, and below the 200-day MA of 181.56, indicating a bearish trend. The MACD of -1.82 indicates Positive momentum. The RSI at 39.74 is Neutral, neither overbought nor oversold. The STOCH value of 17.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7779.

CYBERDYNE Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6678	―	¥16.16B	15.75	―	3.59%	-8.07%	-38.21%
6823	―	¥31.04B	10.51	―	2.67%	7.99%	28.81%
4549	―	¥74.45B	34.68	―	2.40%	3.80%	6.68%
7600	―	¥13.54B	―	―	2.92%	4.84%	-148.94%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
7777	―	$34.74B	-31.75	-49.32%	―	45.67%	29.44%
7779	―	$39.58B	―	-0.82%	―	-5.24%	81.24%

CYBERDYNE Corporate Events

CYBERDYNE Selected for Ukraine Reconstruction Subsidy

CYBERDYNE has been selected for a subsidy under the Japanese government’s program to support Ukraine’s reconstruction. The company will establish a next-generation Cybernics treatment center in Ukraine, partnering with UNBROKEN in Lviv, to aid in the social reintegration of war-affected individuals and restore medical infrastructure.

The most recent analyst rating on (JP:7779) stock is a Hold with a Yen183.00 price target. To see the full list of analyst forecasts on CYBERDYNE stock, see the JP:7779 Stock Forecast page.

CYBERDYNE Reports Revenue Decline but Improved Profits in Q1 2025

CYBERDYNE, INC. reported a decrease in revenue for the three months ending June 30, 2025, with a 13.4% drop compared to the previous year. Despite the revenue decline, the company saw a notable improvement in profits attributable to owners, indicating potential operational efficiencies or cost management strategies. The company did not provide a forecast for the fiscal year ending March 31, 2026, due to uncertainties in its market.

The most recent analyst rating on (JP:7779) stock is a Buy with a Yen365.00 price target. To see the full list of analyst forecasts on CYBERDYNE stock, see the JP:7779 Stock Forecast page.